307 - A Prospective Randomized Trial Comparing Conditioning with Either BEAM or High-Dose Melphalan Prior to Autologous Transplantation for Patients with Multiple Myeloma: An Evaluation of Interim Safety in Early Recovery Phase

Publication Title

Transplantation and Cellular Therapy

Authors

• Megumi Bailey, Swedish Medical Center, Seattle, Washington, United States.Follow
• Tenzin Tsomo, 1Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WAFollow
• Neil Bailey, Swedish Cancer Center, Seattle, WAFollow
• Tori Braun, Swedish Cancer Center, Seattle, WA
• Chiachun Lu, Swedish Cancer Center, Seattle, WA
• Carol Dean, Swedish Cancer Center, Seattle, WA
• Shannon Williams, Swedish Cancer Center, Seattle, WA
• Gayle Funk, Swedish Cancer Center, Seattle, WA
• Joanna Fesler, Swedish Cancer Center, Seattle, WA
• Sonia Glennie, Swedish Cancer Center, Seattle, WA
• Judson Hall, Swedish Cancer Center, Seattle, WA
• Vanessa Dunleavy, Swedish Cancer Center, Seattle, WA
• Daniel N Egan, Department of Medicine, Swedish Medical Center, Seattle, WA, United States.Follow
• Raya Mawad, Department of Medical Oncology, Swedish Cancer Institute, Seattle, WA, USAFollow
• Livia Hegerova, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, Washington.Follow
• Krish Patel, Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USAFollow
• John M PagelFollow
• William Bensinger, Myeloma and Transplant Program, Swedish Cancer Institute, Seattle, WA, United StatesFollow

Document Type

Abstract

Publication Date

3-18-2022

Keywords

washington; swedish; swedish cancer

Area of Special Interest

Cancer

Specialty/Research Institute

Hematology

Specialty/Research Institute

Oncology